KNOTUS Co.Ltd

278650 · KQ · Healthcare / Biotechnology

3,865.00KRW-235.00 (-5.73%)

Price History

Full chart

Market Stats

Previous Close4,100.00

Open4,130.00

Day Range3,855.00 – 4,300.00

52-Week Range1,500.00 – 10,100.00

Volume423.82K

Market Cap49.98B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta-0.01

50-Day Avg2,340.40

200-Day Avg4,743.33

About

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug development consulting and clinical trial services, and bioanalysis items. The company was formerly known as KNOTUS Co.,Ltd. HLB bioStep Co.,Ltd. was founded in 2012 and is headquartered in Incheon, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOIn-Sung Jeong
Employees141
Headquarters38 Academy-ro, Incheon, South Korea, 22014, Korea
Websitehttps://hlbbiostep.com

Leadership

In-Sung JeongCo-Chief Executive Officer
Do-Hyung KimCo-Chief Executive Officer · b. 1980

Financials

Income Statement

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	11.16B	29.34B	37.24B	46.04B	58.52B	64.40B	86.28B	52.81B	58.17B	74.05B
Growth (%)	-	+162.94%	+26.92%	+23.64%	+27.11%	+10.05%	+33.96%	-38.79%	+10.14%	+27.30%
Cost of Revenue	-	9.33B	10.44B	12.37B	15.39B	22.35B	32.88B	16.40B	17.12B	17.62B
Gross Profit	-	20.01B	26.80B	33.67B	43.13B	42.06B	53.40B	36.41B	41.05B	56.43B
Gross Margin	-	68.19%	71.97%	73.14%	73.71%	65.30%	61.89%	68.94%	70.56%	76.20%
Operating Expense	-	15.27B	21.40B	26.94B	34.29B	28.08B	48.34B	37.67B	53.85B	65.05B
Operating Income	3.29B	4.74B	5.40B	6.73B	8.84B	13.98B	5.06B	-1.26B	-12.81B	-8.62B
Operating Margin	29.44%	16.15%	14.50%	14.62%	15.11%	21.71%	5.87%	-2.39%	-22.02%	-11.64%
EBITDA	-	-	-	-	-	-	6.00B	7.27B	-5.97B	-10.74B
EBITDA Margin	-	-	-	-	-	-	6.96%	13.77%	-10.26%	-14.51%
Net Income	2.44B	4.31B	3.55B	4.20B	8.30B	11.03B	-3.00B	-164.04M	-8.56B	-18.96B
Net Income Margin	21.82%	14.70%	9.55%	9.11%	14.19%	17.13%	-3.47%	-0.31%	-14.72%	-25.61%
R&D	-	-	-	852.55M	1.09B	1.16B	978.14M	811.99M	824.35M	936.39M
R&D as % of Total Revenue	-	-	-	1.85%	1.85%	1.81%	1.13%	1.54%	1.42%	1.26%
Interest Expense	0	0	0	550.07M	202.22M	184.70M	4.25B	3.47B	858.96M	2.05B
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	1.19%	0.35%	0.29%	4.92%	6.57%	1.48%	2.77%

Balance Sheet

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	19.53B	32.72B	43.74B	61.53B	74.22B	94.63B	172.19B	171.71B	168.33B	155.58B
Total Liabilities	11.17B	16.68B	23.07B	19.67B	20.57B	30.04B	101.91B	68.14B	56.45B	54.64B
Total Equity	8.36B	16.04B	20.67B	41.86B	53.64B	64.59B	70.28B	101.59B	111.87B	96.27B
Cash	4.86B	7.97B	3.34B	5.20B	8.04B	6.16B	14.87B	68.80B	4.20M	41.16B
Total Debt	2.37B	6.75B	7.75B	6.47B	3.81B	-	-	-	-	-
Net Debt	-	-	-	697.68M	-	8.72B	75.95B	-	-	-

Cash Flow

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	3.13B	5.18B	5.18B	5.18B	11.46B	8.46B	6.48B	5.19B	-11.67B	3.09B
Investing Cash Flow	-1.43B	-15.85B	-15.85B	-15.85B	-7.74B	-19.57B	-80.84B	55.72B	1.47B	-
Financing Cash Flow	720.00M	12.53B	12.53B	12.53B	-877.42M	9.21B	83.06B	-6.99B	-12.43B	-
Capital Expenditure	1.42B	5.55B	5.55B	5.55B	3.95B	19.60B	4.89B	4.01B	8.93B	2.06B
Free Cash Flow	-	-	-	-	6.93B	-9.03B	421.71M	1.19B	-20.60B	1.03B
Dividends Paid	-	-	-	1.13B	1.13B	1.13B	1.53B	-	-	-
FCF to OCF	-	-	-	-	60.43%	-106.69%	6.51%	22.84%	176.50%	33.26%
Dividend Paid to FCF	-	-	-	-	16.34%	-12.54%	362.89%	-	-	-

Earnings

Report Date	May 15, 2020	Aug 14, 2020	Nov 16, 2020	Mar 22, 2021	May 17, 2021	Aug 13, 2021	Nov 12, 2021	Mar 22, 2022	May 16, 2022	Aug 16, 2022	Nov 14, 2022	Feb 8, 2023	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	27.49	29.22	21.78	41.51	29.44	29.00	20.33	62.47	10.18	-4.00	-18.00	-34.16	34.86	16.52	-112.15	50.04	-128.15	-183.69	-29.58	-168.88	-96.51	-248.11	62.01	-834.24	-113.02	-198.92
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	After-hours	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap49.98B

Enterprise Value39.01B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.69

Price / Book0.47

Revenue (TTM)72.15B

Gross Profit (TTM)53.18B

EBITDA-1.48B

Profit Margin-25.54%

Operating Margin-11.86%

Return on Equity-18.71%

Return on Assets-2.59%

Shares Outstanding17.20M

Shares Float14.13M

Beta-0.01

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20221×

22.22Dec 28, 2022

20211×

111.11Dec 29, 2021

20201×

83.33Dec 29, 2020

Stock Splits

May 18, 20261:5
May 31, 20229:1